POCT CRP
[POCT CRP]
EPTIS Ringversuch Nr. 331665 | Letze Änderung 2024-10-01 | URL: https://www.eptis.bam.de/pts331665 https://www.eptis.bam.de/pts331665
| Name des Anbieters | |||||||
| Name des Anbieters | Weqas Weqas | ||||||
| Ansässig in | United Kingdom | ||||||
| Sprache(n) | |||||||
| Anmerkungen | Antimicrobial resistance is a major global healthcare problem, with antibiotics for respiratory infections accounting for around 60% of all primary care prescriptions, which in turn comprise 80% of the total antibiotic burden. C-reactive protein (CRP) is a well-established marker for inflammation and infection and is increasingly used in POCT settings to help guide appropriate prescribing of antibiotics for people with lower respiratory tract infection. The programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. Two liquid human serum samples are distributed bimonthly with a minimum of 12 samples distributed over the year covering a wide clinically relevant range. The samples consist of endogenous samples from normal volunteers and patients, along with additional samples spiked with a highly purified source of human CRP to provide an extended clinical range used for the assessment of patients with ARI and COPD exacerbations. The programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. Key Features: - Commutable, endogenous samples. - Samples targeted at appropriate thresholds for the management of patients with ARI and COPD exacerbations. - Programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/poct-eqa/poct-crp/ or contact@weqas.com | ||||||
| Klassifizierung | |||||||
| Produktgruppen |
Health care / medical devices
|
||||||
| Prüfgebiete |
Medical analysis
|
||||||
| Technische Einzelheiten | |||||||
|
|||||||
| Ringversuchsziele | |||||||
| Zielgruppe des Ringversuchs | The programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. | ||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Weitere Ziele | validation of testing methods | ||||||
| Teilnehmerzahl | |||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/ IEC 17043 |
||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||
| Kosten | |||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regelmässig durchgeführt | Ja (Frequency: Bimonthly. Samples: 2 x 0.5mL. ) | ||||||
| Der Ringversuch wird durchgeführt seit | 2017 | ||||||
| Kontaktdaten des Anbieters | |||||||
| Anbieter | Kontaktperson | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.